- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- FDA advisory panel to consider OTC status of NSAIDs
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
MONTVILLE, N.J. — Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia announced Thursday a three-year extension of Bayer’s sponsorship agreement with the WFH.
The agreement calls for Bayer to serve as the sole sponsor of the WFH’s International Hemophilia Training Centre program and provide support for other activities of the organiztion, such as its website and Congress. The program trains healthcare professionals in developing countries in diagnosis and management of hemophilia and related bleeding disorders.
In addition, Bayer has donated $7 million worth of the hemophilia A treatment Kogenate FS (antihemophilic factor [recombinant]), which will be used for humanitarian aid in countries where people with the disease have limited access to care.
“The International Hemophilia Training Centre program is critical to furthering the treatment of hemophilia and related disorders around the world,” WFH CEO Claudia Black said. “We appreciate our long-standing partnership with Bayer and commend the company on its commitment to the hemophilia community to help us achieve our vision of treatment for all.”